アブストラクト
| Title | SGLT2阻害薬 - CKDの立場から |
|---|---|
| Subtitle | 特集 心腎連関から新薬まで! 心×腎疾患の薬物治療 心腎領域の新薬 |
| Authors | 山田将平, 冨永直人 |
| Authors (kana) | |
| Organization | 川崎市立多摩病院腎臓・高血圧内科 |
| Journal | 月刊薬事 |
| Volume | 64 |
| Number | 4 |
| Page | 742-747 |
| Year/Month | 2022 / 3 |
| Article | 報告 |
| Publisher | じほう |
| Abstract | [Points]●SGLT2阻害薬の一つであるダパグリフロジンが, 2021年8月にわが国にて2型糖尿病非合併例の保存期慢性腎臓病(CKD)患者に対して適応承認された. ●慢性心腎連関(心腎症候群2型と4型)において, SGLT2阻害薬は尿細管での低灌流・低酸素の改善によりその悪循環を断ち切ることで心保護, 腎保護効果(蛋白尿の抑制, 腎機能低下の遅延)をもたらすと考えられる. ●SGLT2阻害薬の使用開始後は, initial dipとよばれる糸球体濾過量(GFR)の低下を認めるが, 投与前の30%以内の低下であれば, 中長期的には腎保護効果が期待できる. ●SGLT2阻害薬による急性腎障害(AKI)予防のため, 投与前評価とsick day ruleの徹底および確認は重要である. ●今後, 保存期CKD患者におけるSGLT2阻害薬の使用に関して, さらなるエビデンスの蓄積が期待される. |
| Practice | 薬学 |
| Keywords |
- 全文ダウンロード： 従量制、基本料金制の方共に803円(税込) です。
参考文献
- 1) Wanner C, et al : Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med, 375 : 323-334, 2016
- 2) Perkovic V, et al : Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med, 380 : 2295-2306, 2019
- 3) Wada T, et al : Clinical impact of albuminuria and glomerular filtration rate on renal and cardiovascular events, and all-cause mortality in Japanese patients with type 2 diabetes. Clin Exp Nephrol, 18 : 613-620, 2014
- 4) Wang H, et al : Connecting tubule glomerular feedback in hypertension. Hypertension, 62 : 738-745, 2013
- 5) Heerspink HJL, et al : Dapagliflozin in patients with chronic kidney disease. N Engl J Med, 383 : 1436-1446, 2020
残りの11件を表示する
- 6) Wheeler DC, et al : Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease : a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol, 9 : 22-31, 2021
- 7) Chertow GM, et al : Effects of dapagliflozin in stage 4 chronic kidney disease. J Am Soc Nephrol, 32 : 2352-2361, 2021
- 8) McMurray JJV, et al : Effect of dapagliflozin on clinical out-comes in patients with chronic kidney disease, with and without cardiovascular disease. Circulation, 143 : 438-448, 2021
- 9) Wheeler DC, et al : A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int, 100 : 215-224, 2021
- 10) Nagasu H, et al : Kidney outcomes associated with SGLT2 inhibitors versus other glucose-lowering drugs in real-world clinical practice : The Japan Chronic Kidney Disease Database. Diabetes Care, 44 : 2542-2551, 2021
- 11) Korner A, et al : Increased renal metabolism in diabetes. Mechanism and functional implications. Diabetes, 43 : 629-633, 1994
- 12) Mazer CD, et al : Effect of empagliflozin on erythropoietin levels, iron stores, and red blood cell morphology in patients with type 2 diabetes mellitus and coronary artery disease. Circulation, 141 : 704-707, 2020
- 13) Mudaliar S, et al : Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUT-COME study? A unifying hypothesis. Diabetes Care, 39 : 1115-1122, 2016
- 14) House AA : Cardiorenal syndrome : new developments in the understanding and pharmacologic management. Clin J Am Soc Nephrol, 8 : 1808-1815, 2013
- 15) Heerspink HJL, et al : Clinical implications of an acute dip in eGFR after SGLT2 inhibitor initiation. Clin J Am Soc Nephrol, 16 : 1278-1280, 2021
- 16) Lam D, et al : Real-life prescribing of SGLT2 inhibitors : How to handle the other medications, including glucose-lowering drugs and diuretics. Kidney360, 2 : 742-746, 2021
